Oxford Biomedica (OXB) Competitors

Genus (LON:GNS) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Which has better earnings and valuation, GNS or OXB?

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£666.67M	2.64	£7.87M	£12.06	222.98
Oxford Biomedica	£98.31M	5.80	-£143.51M	-£134.59	-3.98

Is GNS or OXB more profitable?

Genus has a net margin of 1.18% compared to Oxford Biomedica's net margin of -145.98%. Genus' return on equity of 1.41% beat Oxford Biomedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	1.18%	1.41%	3.31%
Oxford Biomedica	-145.98%	-202.50%	-12.67%

Do analysts recommend GNS or OXB?

Genus currently has a consensus target price of GBX 2,725, suggesting a potential upside of 1.30%. Oxford Biomedica has a consensus target price of GBX 410.33, suggesting a potential downside of 23.47%. Given Genus' stronger consensus rating and higher possible upside, research analysts clearly believe Genus is more favorable than Oxford Biomedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Oxford Biomedica	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Do insiders and institutionals have more ownership in GNS or OXB?

77.8% of Genus shares are held by institutional investors. Comparatively, 64.1% of Oxford Biomedica shares are held by institutional investors. 0.8% of Genus shares are held by insiders. Comparatively, 21.2% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the media favor GNS or OXB?

In the previous week, Oxford Biomedica had 6 more articles in the media than Genus. MarketBeat recorded 11 mentions for Oxford Biomedica and 5 mentions for Genus. Oxford Biomedica's average media sentiment score of 0.45 beat Genus' score of 0.28 indicating that Oxford Biomedica is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Biomedica	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more volatility and risk, GNS or OXB?

Genus has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500.

Summary

Genus beats Oxford Biomedica on 11 of the 16 factors compared between the two stocks.